Brind.
  1. FDA approved Novavax's Nuvaxovid BLA, leading to Sanofi receiving a milestone payment and taking over U.S. commercial leadership.
  2. Novavax and Sanofi announced a partnership to facilitate vaccine access.

Novavax and Sanofi Advance Phase 3 Vaccine Study in Europe

1 report, 1 independent Updated Oct 29
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Novavax announced that a fifth participant received a dose in Sanofi’s Phase 3 influenza-COVID-19 vaccine study in Europe on October 29, 2026. This dosing milestone earned Novavax a $125 million payment under its collaboration agreement with Sanofi. The study is assessing safety and immune responses in adults aged 60 and older, pairing Novavax’s Nuvaxovid with Sanofi’s Efluelda/Fluzone High-Dose influenza vaccine. The agreement requires the study to be conducted in the United States or an EU country.

From econotimes.com

Why it matters

Some supportBrind's analysis of the reports

The milestone payment is tied to the first pivotal trial of a Sanofi influenza-COVID-19 combination product covered by its license with Novavax. Novavax reported that the partnership has generated more than $1 billion in revenue. The study is part of a larger partnership facilitating vaccine access, following FDA approval of Novavax's Nuvaxovid BLA.

Novavax and Sanofi previously announced a partnership to facilitate vaccine access, which followed FDA approval of Novavax's Nuvaxovid BLA and Sanofi taking over U.S. commercial leadership.

From econotimes.com

Who's involved

  • NovavaxLicensed its vaccine technology to Sanofi and received a $125 million milestone payment.
  • SanofiIs conducting the Phase 3 influenza-COVID-19 vaccine study in Europe under the collaboration agreement.

Who could feel it

Possible knock-on effects

These are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.

  • NovavaxSpeculative

    Novavax could see increased funding and revenue from the milestone payment and the ongoing partnership.

  • SanofiSpeculative

    Sanofi could see increased revenue and market access from the successful advancement of the combination product trial.

Keep exploring

Part of

Novavax and Sanofi announced a partnership to facilitate vaccine access. All 1 developments

Within FDA approved Novavax's Nuvaxovid BLA, leading to Sanofi receiving a milestone payment and taking over U.S. commercial leadership.

The entities involved

Coverage

Newest first; wire copies grouped